Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maarten Kraan"'
Autor:
Maarten Kraan
Publikováno v:
The Handbook of Medicinal Chemistry ISBN: 9781788018982
Clinical drug development has changed significantly over the past decades. Supported by great advances in the discovery phase, it has enabled a plethora of options and opportunities to capture the clinical benefits and risks associated with the admin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1ddd4bc549bd1c9594743034c9896ab
https://doi.org/10.1039/9781788018982-00812
https://doi.org/10.1039/9781788018982-00812
Autor:
Anne Kirsten, Torsten Goldmann, Espen Elias Groth, Anna Malmgren, Bengt Larsson, Maarten Kraan, Frauke Pedersen, Mohib Uddin, Gerhard Böttcher, Henrik Watz, Klaus F. Rabe, Florian Stellmacher
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 45:121-123
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b63b5dd9bed71d3d8125b3197f52fb5
https://doi.org/10.1016/j.pupt.2017.05.012
https://doi.org/10.1016/j.pupt.2017.05.012
Autor:
Maarten Kraan, Steffen Schubert, Arend Große, Anatoly Dzgoev, Christopher McCrae, Anabel Guedán, Outi Vaarala, Rebecka Svärd, Jenny Horndahl, Clive G. Jackson, Mary-Ann Skujat, Roberto Solari, Christophe Echeverri, Nicola Williams, Theresia Großkopf, Marcus Ståhlman, Madeleine Rådinger
Publikováno v:
American journal of respiratory cell and molecular biology. 59(6)
Human rhinovirus (RV) infections are a significant risk factor for exacerbations of asthma and chronic obstructive pulmonary disease. Thus, approaches to prevent RV infection in such patients would give significant benefit. Through RNA interference l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f08a64e51160b0a8482dab309f94962e
https://pubmed.ncbi.nlm.nih.gov/30084659
https://pubmed.ncbi.nlm.nih.gov/30084659
Autor:
Anne C. A. Marijnissen, Ruth D E Fritsch-Stork, Floris P J G Lafeber, Marita Olsson, Katerina Pardali, Johannes W. J. Bijlsma, Linda Yrlid, Maarten Kraan, Bart V. J. Cuppen
Publikováno v:
Rheumatology International
Rheumatology International, 37(4), 531. Springer Verlag
Rheumatology International, 37(4), 531. Springer Verlag
A substantial proportion of rheumatoid arthritis (RA)-patients experience an insufficient response to glucocorticoids, an important therapeutic agent in RA. The multidrug-resistance 1 (MDR1) gene product P-glycoprotein (P-gp) is an efflux pump that a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019cf810f7b0345244ef4cd67690fb30
https://dspace.library.uu.nl/handle/1874/349194
https://dspace.library.uu.nl/handle/1874/349194
Autor:
Stephen Delaney, Mark Biffen, David J. Keeling, Ajay Aggarwal, Maarten Kraan, John R. Bell, Sara Asimus, Justine Maltby
Publikováno v:
BMJ Open Respiratory Research
Background Many patients with asthma have a T-helper type 2 (Th2) driven inflammation of the lung, whereas toll-like receptor 7 (TLR7) agonists, by inducing type I interferons, inhibit Th2 responses. In man, oral or parenteral TLR7 agonists can induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb02011816e36d1bec084f4a20210a99
http://europepmc.org/articles/PMC4769423
http://europepmc.org/articles/PMC4769423
Autor:
Maarten Kraan
Clinical drug development has a very long history but is still a very dynamic environment, hence the chapter focuses on clinical trials in pharmaceutical research and their core purpose to acquire data on the safety/tolerability and efficacy of pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::942c749c005848ff9ee782f74bb2f992
https://doi.org/10.1039/9781782621836-00623
https://doi.org/10.1039/9781782621836-00623
Autor:
Jan D. Bos, Christina L Jonckheere, M C Lebre, Danielle M. Gerlag, Arno W R van Kuijk, Menno A. de Rie, Maarten Kraan, Paul P. Tak
Publikováno v:
Arthritis research & therapy, 14(5). BioMed Central
Arthritis Research & Therapy
Arthritis Research & Therapy
Introduction Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. Alefacept (a lymphocyte function-associated antigen (LFA)-3 Ig fusion protein that binds to CD2 and functions as an antagonist to T-cell activation) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceae6a5dd1ae68a5ae33f3527837bc8d
https://doi.org/10.1186/ar4038
https://doi.org/10.1186/ar4038